Novo Nordisk Shares Surge on Amycretin Success
This is a news story, published by CNBC, that relates primarily to Novo Nordisk news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsCNBC news
For more news from CNBC, you can click here:
more news from CNBCAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
amycretin obesity pill. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest flagship obesity drug news, amycretin treatment news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weekly amycretin obesity drugCNBC
•Health
Health
Novo Nordisk shares pop 9% on early-stage weight loss drug trial results

82% Informative
Danish pharmaceutical giant Novo Nordisk reported positive early-stage results for its amycretin obesity drug.
The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks .
Novo said the most adverse effects of the treatment were gastrointestinal, with the vast majority being "mild to moderate in severity".
VR Score
85
Informative language
87
Neutral language
60
Article tone
formal
Language
English
Language complexity
61
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links